Monogram Orthopaedics
MGRM

$2.84

12.35%

Market Cap: $90M

About: Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.

Employees: 28

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

14% more capital invested

Capital invested by funds: $996K [Q1] → $1.13M (+$136K) [Q2]

0.35% more ownership

Funds ownership: 1.31% [Q1] → 1.66% (+0.35%) [Q2]

10% less funds holding

Funds holding: 29 [Q1] → 26 (-3) [Q2]

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for MGRM.

See Analyst Rankings

Financial journalist opinion

Monogram Technologies Upsizes 8.00% Series D Convertible Cumulative Preferred Stock and Warrant Offering to $12.5 Million

AUSTIN, TX / ACCESSWIRE / September 11, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced an upsize of its previously announced continuous offering of units from $10 million to $12.5 million of units. Each unit consists of (a) one share of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") and (b) one common stock purchase warrant to purchase one share of its common stock, $0.001 par value per share (the "Common Stock").

Monogram Technologies Upsizes 8.00% Series D Convertible Cumulative Preferred Stock and Warrant Offering to $12.5 Million

Monogram Technologies Inc. (MGRM) Q2 2024 Earnings Call Transcript

Monogram Technologies Inc. (MGRM) Q2 2024 Earnings Call Transcript

Monogram Technologies Inc. (MGRM) Q2 2024 Earnings Call Transcript

Monogram Technologies Reports Second Quarter 2024 Financial Results

Submitted FDA 510(k) Application and Passed FDA Administrative Review for the mBôs TKA System Secured Initial Strategic Multicenter Clinical Trial Collaboration with Shalby Limited Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESSWIRE / August 14, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the second quarter ended June 30, 2024.

Monogram Technologies Reports Second Quarter 2024 Financial Results

Monogram Technologies Secures Initial Strategic Clinical Trial Collaboration

Clinical Trial Collaboration Follows 510(k) Submission and Passing of FDA Administrative Review; Preludes Planned International Launch for the mBȏs TKA System Strategic Partner Shalby is Recognized as one of the Leading Institutions for Orthopedic Surgeries Worldwide, Performing Over 14,000 Annual Knee Replacement Surgeries Globally AUSTIN, TX / ACCESSWIRE / August 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced its strategic collaboration with Shalby Limited (NSE:SHALBY) ("Shalby"), a global muti-specialty hospital chain and one of India's leading orthopedic hospital groups, to conduct a multicenter clinical trial to demonstrate the safety and effectiveness of the mBȏs TKA System.Shalby is the largest (ranked #1 in arthroplasty by volume) orthopedic hospital chain in the world employing over 4,000 people at 14 hospitals in 13 cities and more than 3 million patients treated. Shalby represents approximately 15% of the organized arthroplasty market in India, which has an approximate market size of 200,000 TKAs per year (with a compound annual growth rate of approximately 20% and a population of 1.4 billion people).

Monogram Technologies Secures Initial Strategic Clinical Trial Collaboration

Monogram Technologies Submits 510(k) Application for mBôs TKA System Clearance

Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive Review FDA Decision is Expected Within 90 Days of Initial Submission; However, the Process May be Paused if Additional Information is Requested AUSTIN, TX / ACCESSWIRE / August 8, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for the Company's mBôs TKA System. The application was submitted on July 19, 2024, and passed the FDA Administrative Review.

Monogram Technologies Submits 510(k) Application for mBôs TKA System Clearance

Monogram Technologies to Host Second Quarter 2024 Business Update Conference Call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time

AUSTIN, TX / ACCESSWIRE / August 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a business update conference call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the second quarter ended June 30, 2024 and to discuss key milestones.

Monogram Technologies to Host Second Quarter 2024 Business Update Conference Call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time

Monogram Technologies to Host Investor and Analyst Tour at its Headquarters in Austin, Texas, on Thursday, June 20th, 2024

Management to Showcase Product Demonstration of mBôs Precision Robotic Surgical System and mVision Technologies AUSTIN, TX / ACCESSWIRE / June 3, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will host an investor and analyst day on Thursday, June 20th, 2024, from 9:00 a.m. CDT to 1:00 p.m.

Monogram Technologies to Host Investor and Analyst Tour at its Headquarters in Austin, Texas, on Thursday, June 20th, 2024

Monogram Technologies Inc. (MGRM) Q1 2024 Earnings Call Transcript

Monogram Technologies Inc. (NASDAQ:MGRM ) Q1 2024 Earnings Conference Call May 22, 2024 4:30 PM ET Company Participants Larry Holub - Investor Relations, MZ Group North America Noel Knape - Chief Financial Officer Ben Sexson - Chief Executive Officer Larry Holub Welcome to the Monogram Technologies First Quarter 2024 Business Update Conference Call. I'm Larry Holub, Director at MZ Group North America, representing Monogram Technologies as their external Investor Relations Adviser.

Monogram Technologies Inc. (MGRM) Q1 2024 Earnings Call Transcript

Monogram Orthopaedics Completes Corporate Name Change to Monogram Technologies

New Name Reflects Continued Evolution as an AI-Driven Robotics Company with a Strong IP Position AUSTIN, TX / ACCESSWIRE / May 15, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced its plan to merge its wholly owned subsidiary, Monogram Technologies Inc. ("MT") with and into Monogram Orthopaedics Inc. In connection with this upstream merger, the current MT will cease to exist, and Monogram's business will continue as it is currently being conducted. Further, on May 15, 2024, the effective date of the merger, the Company will change its name to Monogram Technologies Inc., and its ticker will remain "MGRM.

Monogram Orthopaedics Completes Corporate Name Change to Monogram Technologies

Monogram Orthopaedics Reports First Quarter 2024 Financial Results

Verification and Validation Testing Expected to be Largely Complete in Q2 2024; 510(k) Submission with FDA Accelerated for Second Half of 2024 Engaged Contract Research Organization to Oversee mBôs Robot Clinical Trial Activities Outside the U.S. Management to Host Business Update Conference Call on Wednesday, May 22 at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESSWIRE / May 14, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2024.

Monogram Orthopaedics Reports First Quarter 2024 Financial Results

See News Rankings